MRNA vaccine

Virtual twin to improve treatment with cancer immunotherapies

Retrieved on: 
Wednesday, December 13, 2023
Multiple myeloma, Research, Business development, Fraunhofer Society, Investment, Disease, Collection, Clinical trial, Hematology, Oncology, Patient, Radiation, Immunology, European, Malignancy, Science, Machine learning, Cell therapy, Diagnosis, Cancer, MRNA vaccine, Doctor of Philosophy, Bone marrow, Pharmaceutical industry, Medical imaging

Together with partners from science, industry and the healthcare sector, the project team led by the Fraunhofer Institute for Cell Therapy and Immunology IZI aims to develop a virtual twin that will improve treatment with personalized cancer immunotherapies in the future.

Key Points: 
  • Together with partners from science, industry and the healthcare sector, the project team led by the Fraunhofer Institute for Cell Therapy and Immunology IZI aims to develop a virtual twin that will improve treatment with personalized cancer immunotherapies in the future.
  • In recent years, cancer immunotherapies have established themselves as a further pillar of medical oncology alongside traditional treatment options (surgery, radiotherapy and chemotherapy).
  • In the EU project CERTAINTY, modules are now to be developed for a corresponding virtual twin for the treatment of cancer patients with CAR-T cell therapies.
  • The EU consortium "CERTAINTY - A cellular immunotherapy virtual twin for personalized cancer treatment" is being funded by the European Union with almost EUR 10 million over the next 4.5 years.

Global mRNA Vaccine Market Research Report 2023: On-going Clinical Trials, Drug Pipeline, Mergers & Acquisitions, & Product Launches - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023
Health, Pharmaceutical, Perelman School of Medicine at the University of Pennsylvania, Pharmacology, Infection, ClinicalTrials.gov, Vaccine, SARS-CoV-2, RNA, Antigen, Biotechnology, Mortality, Penn, Mutation, Safety, HIV, Cytokine, University, TSA, Research, Cell, Protein, Arcturus Therapeutics, Application, Death, COVID-19 vaccine, Pfizer, Growth, Genome, Vaccination, Lipid, COVID-19, Risk, Viral, Immunity, TAA, Competition, Messenger, DSM-IV codes, MRNA vaccine, Cancer, Investment, Therapy, Patient, Toxicity, Zika virus, Rabies virus, DNA

Global mRNA vaccine market is poised to grow at an impressive rate to 2028 on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others.

Key Points: 
  • Global mRNA vaccine market is poised to grow at an impressive rate to 2028 on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others.
  • The global mRNA vaccine market experiences growth driven by the increasing occurrence of cancer, genetic anomalies, and viral infections.
  • This has prompted numerous biotechnology and pharmaceutical companies, along with academic and research institutions, to engage in research, development, and clinical trials for various mRNA vaccines.
  • This, in turn, creates promising prospects for the global mRNA vaccine market during the forecast period.

Cellecta, Inc. Launches Genome-Wide CRISPR Chicken and Pig Knockout Libraries

Retrieved on: 
Monday, October 9, 2023
Research and development, Livestock, Wild boar, Breeding, RNA, NGS, MRNA vaccine, Red junglefowl, HEAT, CRISPR, Gene, Poultry, Sus, Gallus, Library, Meat, Genome, Agriculture, Animal husbandry

MOUNTAIN VIEW, Calif., Oct. 9, 2023 /PRNewswire/ -- Cellecta, Inc. today announced the release of new pooled, single-module, CRISPR genome-wide knockout libraries for chicken (Gallus gallus) and pig (Sus scrofa). These new CRISPR libraries, with 4 guide RNAs (sgRNA) per gene, include:

Key Points: 
  • MOUNTAIN VIEW, Calif., Oct. 9, 2023 /PRNewswire/ -- Cellecta, Inc. today announced the release of new pooled, single-module, CRISPR genome-wide knockout libraries for chicken (Gallus gallus) and pig (Sus scrofa).
  • These CRISPR Chicken Genome 69K and Pig Genome 89K Knockout Libraries incorporate Cellecta's more effective HEAT1 sgRNA structure.
  • "We are pleased to offer one of the few commercially available, genome-wide CRISPR knockout libraries for researchers working with livestock and poultry," stated Donato Tedesco, Ph.D., Cellecta Director of Research & Development.
  • Cellecta's pooled single-module CRISPR Chicken Genome 69K and Pig Genome 89K Knockout Libraries are available now.

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government

Retrieved on: 
Wednesday, October 4, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Vaccine, DNA, Diversified Specialty Institute Holdings, Inc., Therapy, Arcturus Therapeutics, Infection, ARCT, RNA, Messenger, MRNA vaccine, Liver, Arcturus

In total to date, $165 million has been awarded to ARCALIS by the Japanese government to build mRNA Drug Substance, mRNA Drug Product manufacturing capabilities and to construct a DNA template manufacturing facility.

Key Points: 
  • In total to date, $165 million has been awarded to ARCALIS by the Japanese government to build mRNA Drug Substance, mRNA Drug Product manufacturing capabilities and to construct a DNA template manufacturing facility.
  • The mRNA Drug Substance manufacturing facility was completed in July 2023.
  • ARCALIS will provide cGMP-integrated vaccine manufacturing, from mRNA drug substance to bulk nanoparticle-formulated drug product.
  • “This support has already enabled the completion of a state-of-the-art mRNA Drug Substance manufacturing facility, and we are excited to now extend this collaboration with the construction of an associated DNA manufacturing facility.

GenScript Doubles cGMP sgRNA and Non-Viral DNA Payload Manufacturing Capacity

Retrieved on: 
Thursday, July 6, 2023
GMP, DNA, CRISPR, Facility, File, GenScript Biotech, HDR, Doctor of Philosophy, EMA, HS, Documentation, CGMP, MD, UCSF, Patient, PMDA, Growth, FDA, MRNA vaccine, IND, NMPA, Vaccine, Fine chemical

PISCATAWAY, N.J., July 6, 2023 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has expanded its cGMP manufacturing capacity for sgRNA and non-viral DNA payloads with a new, state-of-the-art facility in Zhenjiang, Jiangsu, China. This latest expansion provides biopharma companies and gene and cell therapeutic discovery startups a fast-turnaround source of the quality components needed to advance novel therapies from the bench to the clinic and onto the market in less time.

Key Points: 
  • at GenScript's cGMP facility in Zhenjiang, China gives biopharma companies and gene/cell therapeutic discovery startups fast access to synthetic CRISPR sgRNA and non-viral single and double-stranded DNA payloads
    PISCATAWAY, N.J., July 6, 2023 /PRNewswire/ -- GenScript Biotech Corporation , the world's leading provider of life-science research tools and services, has expanded its cGMP manufacturing capacity for sgRNA and non-viral DNA payloads with a new, state-of-the-art facility in Zhenjiang, Jiangsu, China .
  • ft. cGMP plant in Nanjing, comprising five cGMP production lines for synthetic CRISPR sgRNA and non-viral DNA payloads.
  • "GenScript is pleased to complete the expansion of our manufacturing capacity of cGMP sgRNA and non-viral DNA payloads for IND filing and clinical trials," said Ray Chen, president of the Life Science Group at GenScript.
  • The opening of our newest cGMP manufacturing facility represents our strong commitment to supporting our gene and cell therapy customers."

mRNA Vaccine and Therapeutics Market to Hit USD 68.1 Billion by 2030 With Growing Demand of Vaccines to Treat Infectious Diseases, States Extrapolate

Retrieved on: 
Tuesday, May 23, 2023
Chapter Eight, Chapter 11, Title 11, United States Code, MRNA vaccine, Chapter Seven, Application, Chapter Nine, Therapy, Chapter Five, Chapter Six, Chapter Ten, Geography, Vaccine, Pharmaceutical industry

Global MRNA Vaccine and Therapeutics Market Overview, By Product, 2018 - 2032 (USD Million)

Key Points: 
  • Global MRNA Vaccine and Therapeutics Market Overview, By Product, 2018 - 2032 (USD Million)
    5.1.
  • Global MRNA Vaccine and Therapeutics Market Share, By Product, 2018 - 2032 (USD Million)
    Chapter 6.
  • Global MRNA Vaccine and Therapeutics Market Overview, By Disease Type, 2018 - 2032 (USD Million)
    6.1.
  • Global MRNA Vaccine and Therapeutics Market Share, By Disease Type, 2018 - 2032 (USD Million)
    Chapter 7.

mRNA Vaccine and Therapeutics Market to Hit USD 68.1 Billion by 2030 With Growing Demand of Vaccines to Treat Infectious Diseases, States Extrapolate

Retrieved on: 
Tuesday, May 23, 2023
Chapter Eight, Chapter 11, Title 11, United States Code, MRNA vaccine, Chapter Seven, Application, Chapter Nine, Therapy, Chapter Five, Chapter Six, Chapter Ten, Geography, Vaccine, Pharmaceutical industry

Global MRNA Vaccine and Therapeutics Market Overview, By Product, 2018 - 2032 (USD Million)

Key Points: 
  • Global MRNA Vaccine and Therapeutics Market Overview, By Product, 2018 - 2032 (USD Million)
    5.1.
  • Global MRNA Vaccine and Therapeutics Market Share, By Product, 2018 - 2032 (USD Million)
    Chapter 6.
  • Global MRNA Vaccine and Therapeutics Market Overview, By Disease Type, 2018 - 2032 (USD Million)
    6.1.
  • Global MRNA Vaccine and Therapeutics Market Share, By Disease Type, 2018 - 2032 (USD Million)
    Chapter 7.

Kanazawa University research: Detect, bind and cut: biomolecular action at the nanoscale

Retrieved on: 
Tuesday, March 7, 2023
Lens, X-ray crystallography, Kanazawa University, Staphylococcus aureus, Staphylococcus, Research, CRISPR, ACS Nano, Bacteria, DNA, MRNA vaccine, AFM, Gene editing, Virus, RNA, ACS, Map, Microscope, Vaccine, Cas9

KANAZAWA, Japan, March 7, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in ACS Nano how high-speed atomic force microscopy can be used to study the biomolecular mechanisms underlying gene editing.

Key Points: 
  • KANAZAWA, Japan, March 7, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in ACS Nano how high-speed atomic force microscopy can be used to study the biomolecular mechanisms underlying gene editing.
  • Sometimes, however, the wrong target is 'caught' by Cas9 — when the wrongly identified DNA sequence is too similar to the intended target sequence.
  • It is therefore of crucial importance to fully understand how Cas9 binds to, 'interrogates', and cuts DNA.
  • Researchers at Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time.

Kanazawa University research: Detect, bind and cut: biomolecular action at the nanoscale

Retrieved on: 
Tuesday, March 7, 2023
Lens, X-ray crystallography, Kanazawa University, Staphylococcus aureus, Staphylococcus, Research, CRISPR, ACS Nano, Bacteria, DNA, MRNA vaccine, AFM, Gene editing, Virus, RNA, ACS, Map, Microscope, Vaccine, Cas9

KANAZAWA, Japan, March 7, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in ACS Nano how high-speed atomic force microscopy can be used to study the biomolecular mechanisms underlying gene editing.

Key Points: 
  • KANAZAWA, Japan, March 7, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in ACS Nano how high-speed atomic force microscopy can be used to study the biomolecular mechanisms underlying gene editing.
  • Sometimes, however, the wrong target is 'caught' by Cas9 — when the wrongly identified DNA sequence is too similar to the intended target sequence.
  • It is therefore of crucial importance to fully understand how Cas9 binds to, 'interrogates', and cuts DNA.
  • Researchers at Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time.

Indee Labs Partners with GenScript to Develop Direct DNA Knock-in Kit for Large Transgene Inserts

Retrieved on: 
Thursday, February 16, 2023
DNA, AAV, Messenger, Electroporation, Indee Gold Mine, RNP, MRNA vaccine, RUO, CRISPR, Cell, HDR, GenScript Biotech, Transgene, Genome, Uniloc USA, Inc. v. Microsoft Corp., Doctor of Philosophy, Vaccine

BERKELEY, Calif., Feb. 16, 2023 /PRNewswire/ -- Indee Labs, the developer of Hydropore™ for non-viral intracellular delivery, is partnering with GenScript USA Inc., the world's leading provider of life-science research tools and services, to deliver GenScript's non-viral DNA payloads into cells at greater efficiency, and to enable the integration of longer DNA inserts than those allowed by traditional viral methods.

Key Points: 
  • As part of the collaboration, GenScript is providing a variety of single-strand and double-strand (ssDNA and dsDNA) constructs for direct DNA inserts, while the team at Indee Labs is optimizing the Hydropore protocol and evaluating functional differences between T cells processed with Hydropore and electroporation.
  • Looking ahead, the companies will work on co-marketing a complete non-viral solution to the gene and cell therapy community.
  • One powerful application of CRISPR/Cas genome editing technology involves the precise insertion of DNA sequences via the homology-directed repair (HDR) pathway.
  • We are now excited to focus on enabling direct DNA inserts using GenScript's DNA capabilities," said Ryan Pawell, CEO of Indee Labs.